Nanoplasmid™ Vector Design/Retrofit

Nanoplasmid Vector Design/Retrofit

The Power of a Small Backbone for Gene & Cell Therapies

Nanoplasmid vectors are easily substituted for conventional plasmids, minicircles, doggy bone DNA, etc., for use with all major downstream vector technologies. The Nanoplasmid backbone was modified to remove bacterial coding sequences, uses an antibiotic-free selection system, and has profound beneficial effects on performance across a range of gene, cell, and mRNA therapies and vaccines including:

Nanoplasmid Retrofit & Design Services

Our Nanoplasmid experts will work with you to either design a Nanoplasmid from scratch or retrofit an existing, traditional plasmid into a high-performing Nanoplasmid alternative, including sequence verification and DNA production. A retrofit entails sending us 10 micrograms of your plasmid (on filter paper or in liquid form). We will swap your current plasmid backbone for the Nanoplasmid version, verify the construct, and return the desired quantity of the amplified product.

Nanoplasmid Manufacturing

Nanoplasmids combine the improved performance of minicircles with the manufacturing attributes of traditional plasmids. Therefore, our custom plasmid DNA manufacturing services are available for both Nanoplasmids and traditional plasmids.

Expression Example

Retrofitting a pVAX plasmid (1) with RNA-OUT (antibiotic free) selectable marker (2), or (3) with Nanoplasmid™ (RNA-OUT plus R6K ori), or (4)with Nanoplasmid™ plus BGH poly(A), dramatically improves expression, up to ten (or more) fold. Scale: Fluorescence Units (FU).


Nanoplasmid is a disruptive technology in the clinical and pre-clinical arena. There have been dozens of publications showing off how this small backbone delivers powerful benefits.

  • Boye C, Arpag S, Burcus N, Lundberg C, DeClemente S, Heller R, Francis M, Bulysheva A. Cardioporation enhances myocardial gene expression in rat heart. Bioelectrochemistry. 2021 Dec;142:107892. doi: 10.1016/j.bioelechem.2021.107892. Epub 2021 Jul 27. PMID: 34371349.

Showing improved electroporation transfection methods in vivo and in vitro using Nanoplasmid versus conventional plasmids for naked DNA expression.

  • Oh SA, Senger K, Madireddi S, Akhmetzyanova I, Ishizuka IE, Tarighat S, et al. High-efficiency nonviral CRISPR/cas9-mediated gene editing of human T cells using plasmid donor DNA. Journal of Experimental Medicine. 2022;219(5).

This publication showed improved CAR-T knock-in efficiency, reduced cell death, and an improved T cell phenotype for CAR-T cell therapies using Nanoplasmid compared to conventional plasmids and linear DNA as an HDR template.

  • Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Science Advances. 2021;7(16). doi: 10.1126/sciadv.abf1333

This article discussed how Nanoplasmid was integrated into a rapid and novel manufacturing workflow for the production of CAR-T cell therapies for patients.

For more information on these and other applications, download the complete bibliography.

Contact a Nanoplasmid Expert